(XBI) SPDR S&P Biotech - Ratings and Ratios
Stocks, Biotech, Small-Cap, Mid-Cap, Equal-Weight
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.9% |
| Value at Risk 5%th | 42.9% |
| Relative Tail Risk | 2.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.46 |
| Alpha | 0.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.321 |
| Beta | 0.925 |
| Beta Downside | 0.887 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.99% |
| Mean DD | 10.92% |
| Median DD | 10.15% |
Description: XBI SPDR S&P Biotech November 06, 2025
The SPDR S&P Biotech ETF (ticker XBI) aims to replicate the S&P Biotechnology Select Industry Index by using a sampling approach, allocating at least 80 % of its assets to the index’s constituents. The index captures the biotech segment of the broader S&P Total Market Index, providing exposure to a diversified basket of U.S. biotechnology firms.
Key quantitative details (as of the latest filing) include an expense ratio of roughly 0.35 %, about 140 holdings with a median market-cap near $2 billion, and a weighted average dividend yield close to 0 % (reflecting the sector’s growth focus). Recent performance has been driven by a surge in FDA approvals-biotech companies saw a 12 % YoY increase in new drug clearances in 2024-and robust R&D spending, which grew at an annualized 8 % rate, supporting pipeline expansion.
Macro-level drivers such as U.S. healthcare policy stability, the pace of gene-therapy commercialization, and the availability of venture capital continue to shape sector risk-reward dynamics.
For a deeper dive into XBI’s valuation metrics and risk profile, you might explore the analysis on ValueRay.
XBI ETF Overview
| Market Cap in USD | 6,608m |
| Category | Health |
| TER | 0.35% |
| IPO / Inception | 2006-01-31 |
| Return 12m vs S&P 500 | 7.26% |
| Analyst Rating | - |
XBI Dividends
| Dividend Yield | 0.04% |
| Yield on Cost 5y | 0.03% |
| Yield CAGR 5y | -17.13% |
| Payout Consistency | 46.7% |
| Payout Ratio | - |
XBI Growth Ratios
| CAGR 3y | 12.26% |
| CAGR/Max DD Calmar Ratio | 0.37 |
| CAGR/Mean DD Pain Ratio | 1.12 |
| Current Volume | 14432.7k |
| Average Volume | 11352.6k |
What is the price of XBI shares?
Over the past week, the price has changed by +3.56%, over one month by +5.65%, over three months by +26.42% and over the past year by +24.03%.
Is SPDR S&P Biotech a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XBI is around 108.50 USD . This means that XBI is currently overvalued and has a potential downside of -4.83%.
Is XBI a buy, sell or hold?
What are the forecasts/targets for the XBI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 122 | 7% |
XBI Fundamental Data Overview November 15, 2025
Beta = 1.26
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 6.61b USD (6.61b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 6.61b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 6.61b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.42% (E(6.61b)/V(6.61b) * Re(9.42%) + (debt-free company))
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for XBI ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle